Latest Industry Insights

Technology Networks spoke with Jonathan Hare, PhD, Imophoron’s Head of Immunology, to learn more about the ADDomer™ vaccine platform, the benefits of administering vaccines by a variety of administrative routes and the infectious diseases they are currently working to develop vaccines for.

Technology Networks spoke to Mani Krishnan to learn how a new category of analytical instrumentation – imaged capillary isoelectric mass spectrometry (icIEF-MS) – is helping to accelerate the biotherapeutic development process.

In this interview, Murat Kalayoglu, president and CEO of Cartesian Therapeutics discusses the company’s efforts to develop RNA-modified cell therapies that expand past oncology.

Agilent recently announced its commitment to achieve net-zero greenhouse gas emissions no later than 2050. We spoke to them to learn how you go about making a global company with 16,300 employees a net-zero business.

Here we highlight some of the innovations featured at the 69^th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics.

While many of us are still attending events remotely, ASMS 2021 has been in full swing this year with in-person talks and events. To give you a taste of the topics proving popular this year, Technology Networks has produced a round up to highlight a selection of key themes and innovations.

The focus on COVID-19 has caused many trials to be delayed, canceled or scaled back – meaning that the development of new medicines for patients in other areas has been slowed. At the same time, it has exposed pre-existing flaws in the industry. To recover from the pandemic, the industry must now address these underlying issues.

To learn more about the Biophase 8800 system and how it can help to overcome current bioanalytical challenges, Technology Networks spoke to Mani Krishnan, vice president and general manager, SCIEX CE and Biopharma.

To learn more about a universal vaccine technology and how the platform could be applied to Alzheimer's disease and other neurological indications, Technology Networks spoke with Roman Kniazev, chief executive officer at Nuravax.

In recent years, a number of new cell and gene therapies have been developed to treat a variety of indications, including cancer and inherited retinal dystrophies. While these therapies have proven to be beneficial to patients, their scalability and manufacturability are two enduring challenges. Technology Networks spoke to Tara St.Amand, PhD, MBA, director of business technology, bioprocess at Corning to learn more about the key challenges faced when scaling up the manufacturing of cell products.